Pharmaceutical

Intellia’s gene editing therapy shows early potential in rare heart condition

Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in Chicago.

Nov 19, 2024 - 06:00
Intellia’s gene editing therapy shows early potential in rare heart condition
Intellia presented data from its Phase I study of NTLA-2001 at the 2024 American Heart Association scientific meeting in Chicago.
Read the original article

Tags:

Previous Article

AstraZeneca picks first Treg cell therapy from Quell Therapeutics partnership

Next Article

Sandoz’s Afqlir gains EC marketing authorisation for retinal diseases

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Amylyx ALS drug failure leaves patients, advocates, and researchers reeling — and wondering what’s next

STAT+: Amylyx ALS drug failure leaves patients, advocat...

Mar 8, 2024

STAT+: Could a fight over cost-effectiveness upend Medicare drug price negotiation before it’s begun?

STAT+: Could a fight over cost-effectiveness upend Medi...

Mar 28, 2023

STAT+: Drug shortages and the supply chain are a matter of national security, experts say

STAT+: Drug shortages and the supply chain are a matter...

Nov 7, 2023